CSIMarket


Enzon Pharmaceuticals inc   (ENZN)
Other Ticker:  
 

Enzon Pharmaceuticals inc

ENZN's Fundamental analysis








Looking into Enzon Pharmaceuticals Inc growth rates, revenue grew by 5.14 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1690

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 13.29 %

Enzon Pharmaceuticals Inc 's net profit decreased by -20.87 % in III. Quarter 2024 year on year, to $0 millions.

More on ENZN's Growth


Enzon Pharmaceuticals Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 158.2 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
24276.4
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 6.12.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.44.


More on ENZN's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0.02 $
 Dividend Yield TTM (%) 12.35 %
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) 0.04

Enzon Pharmaceuticals Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 158.2 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
24276.4
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 6.12.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.44.

Enzon Pharmaceuticals Inc Price to Book Ratio is at 4.35 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02

More on ENZN's Valuation

  Market Capitalization (Millions $) 12
  Shares Outstanding (Millions) 74
  Employees -
  Revenues (TTM) (Millions $) 2
  Net Income (TTM) (Millions $) 2
  Cash Flow (TTM) (Millions $) 0
  Capital Exp. (TTM) (Millions $) -
  Total Debt (Millions $) -
  Dividend TTM ($) 0.02 $
  Dividend Yield TTM (%) 12.35 %
  Revenue/Employee (TTM) $ -
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) -
  Tangible Book Value (Per Share $) 0.04

  Market Capitalization (Millions $) 12
  Shares Outstanding (Millions) 74
  Employees -
  Revenues (TTM) (Millions $) 2
  Net Income (TTM) (Millions $) 2
  Cash Flow (TTM) (Millions $) 0
  Capital Exp. (TTM) (Millions $) -





  Ratio
   Capital Ratio (MRQ) 107.24
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) 16.12
  Asset Turnover Ratio (TTM) 0.04
  Inventory Turnover Ratio (TTM) -





Enzon Pharmaceuticals Inc net profit margin of 38.84 % is currently ranking no. 4 in Biotechnology & Pharmaceuticals industry, ranking no. 22 in Healthcare sector and number 211 in S&P 500.

More on ENZN's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com